Article Text

Download PDFPDF

Antibiotic therapy for pelvic inflammatory disease: an abridged version of a Cochrane systematic review and meta-analysis of randomised controlled trials
  1. Ricardo F Savaris1,
  2. Daniele G Fuhrich1,
  3. Rui V Duarte2,
  4. Sebastian Franik3,
  5. Jonathan D C Ross4
  1. 1 Ginecologia e Obstetricia, Universidade Federal do Rio Grande do Sul-FAMED, Porto Alegre, Brazil
  2. 2 Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
  3. 3 Department of Gynaecology and Obstetrics, Münster University Hospital, Münster, Germany
  4. 4 Whittall Street Clinic, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
  1. Correspondence to Rui V Duarte, Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool L69 3GB, UK; rui.duarte{at}liverpool.ac.uk

Footnotes

  • Handling editor Nicola Low

  • Contributors RFS: coordination, study design, statistical analysis and review, writing the manuscript, grading the evidence in GRADE, and final approval of the manuscript. DGF: data collection, extraction, grading the risk of bias and final approval of the manuscript. RVD: data collection, extraction, grading the risk of bias, writing the manuscript and final approval of the manuscript. SF: data collection, extraction, grading the risk of bias, grading the evidence in GRADE and final approval of the manuscript. JR: study design, writing the manuscript, grading the evidence in GRADE and final approval of the manuscript.

  • Funding NIHR’s 2012 Cochrane Review Incentive Scheme Award, UK.

  • Competing interests RFS, DGF, RVD and SF certify that they do not have any affiliations with, or involvement in, any organisation or entity with a direct financial interest in the subject matter of this review (eg, employment, consultancy, stock ownership, honoraria, expert testimony). JR declares the following interests: personal fees from GSK Pharma, Hologic Diagnostic and Janssen Pharma; ownership of shares in GSK Pharma and AstraZeneca Pharma; author of the UK and European Guidelines on Pelvic Inflammatory Disease; member of the European Sexually Transmitted Infections Guidelines Editorial Board; member of the National Institute for Health Research (NIHR) HTA Commissioning Board; NIHR Journals Editor; Editorial Board of the Cochrane Collaboration Sexually Transmitted Diseases Collaborative Review Group; and Sexually Transmitted Infections journal associate editor. The authors disclose that two of the authors (RFS and JR) had two publications used in the analysis. RFS and JR did not participate in the process for considering these studies for inclusion, data extraction, quality assessment and grading for risk of bias. The current article is based on a published Cochrane review.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Handling editor Nicola Low

  • Contributors RFS: coordination, study design, statistical analysis and review, writing the manuscript, grading the evidence in GRADE, and final approval of the manuscript. DGF: data collection, extraction, grading the risk of bias and final approval of the manuscript. RVD: data collection, extraction, grading the risk of bias, writing the manuscript and final approval of the manuscript. SF: data collection, extraction, grading the risk of bias, grading the evidence in GRADE and final approval of the manuscript. JR: study design, writing the manuscript, grading the evidence in GRADE and final approval of the manuscript.

  • Funding NIHR’s 2012 Cochrane Review Incentive Scheme Award, UK.

  • Competing interests RFS, DGF, RVD and SF certify that they do not have any affiliations with, or involvement in, any organisation or entity with a direct financial interest in the subject matter of this review (eg, employment, consultancy, stock ownership, honoraria, expert testimony). JR declares the following interests: personal fees from GSK Pharma, Hologic Diagnostic and Janssen Pharma; ownership of shares in GSK Pharma and AstraZeneca Pharma; author of the UK and European Guidelines on Pelvic Inflammatory Disease; member of the European Sexually Transmitted Infections Guidelines Editorial Board; member of the National Institute for Health Research (NIHR) HTA Commissioning Board; NIHR Journals Editor; Editorial Board of the Cochrane Collaboration Sexually Transmitted Diseases Collaborative Review Group; and Sexually Transmitted Infections journal associate editor. The authors disclose that two of the authors (RFS and JR) had two publications used in the analysis. RFS and JR did not participate in the process for considering these studies for inclusion, data extraction, quality assessment and grading for risk of bias. The current article is based on a published Cochrane review.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles